NCT06486779 - Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

December 30, 2028

Study Completion Date

December 30, 2028

Conditions

Relapsing Multiple Sclerosis (RMS)

Interventions

OTHER

Ofatumumab

This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.

Trial Locations (13)

12462

RECRUITING

Novartis Investigative Site, Chaïdári

18547

RECRUITING

Novartis Investigative Site, Athens

53246

RECRUITING

Novartis Investigative Site, Greece

681 00

RECRUITING

Novartis Investigative Site, Alexandroupoli

115 21

RECRUITING

Novartis Investigative Site, Athens

714 09

RECRUITING

Novartis Investigative Site, Crete Heraklion

265 00

RECRUITING

Novartis Investigative Site, Pátrai

115 25

RECRUITING

Novartis Investigative Site, Athens

115 27

RECRUITING

Novartis Investigative Site, Athens

455 00

RECRUITING

Novartis Investigative Site, Ioannina

411 10

RECRUITING

Novartis Investigative Site, Larissa

115 28

RECRUITING

Novartis Investigative Site, Athens

GR 54636

RECRUITING

Novartis Investigative Site, Thessaloniki